Literature DB >> 12415308

The immunology of susceptibility and resistance to Leishmania major in mice.

David Sacks1, Nancy Noben-Trauth.   

Abstract

Established models of T-helper-2-cell dominance in BALB/c mice infected with Leishmania major -- involving the early production of interleukin-4 by a small subset of Leishmania-specific CD4+ T cells -- have been refined by accumulating evidence that this response is not sufficient and, under some circumstances, not required to promote susceptibility. In addition, more recent studies in L. major-resistant mice have revealed complexities in the mechanisms responsible for acquired immunity, which necessitate the redesign of vaccines against Leishmania and other pathogens that require sustained cell-mediated immune responses.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12415308     DOI: 10.1038/nri933

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  448 in total

1.  Mast cell IL-4 expression is regulated by Ikaros and influences encephalitogenic Th1 responses in EAE.

Authors:  Gregory D Gregory; Shveta S Raju; Susan Winandy; Melissa A Brown
Journal:  J Clin Invest       Date:  2006-04-20       Impact factor: 14.808

Review 2.  Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens.

Authors:  Douglas S Watson; Aaron N Endsley; Leaf Huang
Journal:  Vaccine       Date:  2012-02-02       Impact factor: 3.641

3.  Effects of CXCL10 on dendritic cell and CD4+ T-cell functions during Leishmania amazonensis infection.

Authors:  René E Vasquez; Lijun Xin; Lynn Soong
Journal:  Infect Immun       Date:  2007-11-12       Impact factor: 3.441

4.  In vitro antileishmanial activity of resveratrol and its hydroxylated analogues against Leishmania major promastigotes and amastigotes.

Authors:  Lukasz Kedzierski; Joan M Curtis; Milena Kaminska; Jadwiga Jodynis-Liebert; Marek Murias
Journal:  Parasitol Res       Date:  2007-09-01       Impact factor: 2.289

5.  Hypoxia in Leishmania major skin lesions impairs the NO-dependent leishmanicidal activity of macrophages.

Authors:  Alexander Mahnke; Robert J Meier; Valentin Schatz; Julian Hofmann; Kirstin Castiglione; Ulrike Schleicher; Otto S Wolfbeis; Christian Bogdan; Jonathan Jantsch
Journal:  J Invest Dermatol       Date:  2014-02-28       Impact factor: 8.551

6.  Immunological determinants of clinical outcome in Peruvian patients with tegumentary leishmaniasis treated with pentavalent antimonials.

Authors:  Anne Maurer-Cecchini; Saskia Decuypere; François Chappuis; Coralie Alexandrenne; Simonne De Doncker; Marleen Boelaert; Jean-Claude Dujardin; Louis Loutan; Jean-Michel Dayer; Gianfranco Tulliano; Jorge Arevalo; Alexandro Llanos-Cuentas; Carlo Chizzolini
Journal:  Infect Immun       Date:  2009-02-23       Impact factor: 3.441

Review 7.  Pro- and anti-inflammatory cytokines in cutaneous leishmaniasis: a review.

Authors:  Nahid Maspi; Amir Abdoli; Fathemeh Ghaffarifar
Journal:  Pathog Glob Health       Date:  2016-09-23       Impact factor: 2.894

8.  UNC93B1 and nucleic acid-sensing Toll-like receptors mediate host resistance to infection with Leishmania major.

Authors:  Bruno Luiz Fonseca Schamber-Reis; Patricia M Petritus; Braulia C Caetano; Espiridion R Martinez; Kendi Okuda; Douglas Golenbock; Phillip Scott; Ricardo T Gazzinelli
Journal:  J Biol Chem       Date:  2013-01-16       Impact factor: 5.157

Review 9.  Induction and regulation of pathogenic Th17 cell responses in schistosomiasis.

Authors:  Bridget M Larkin; Patrick M Smith; Holly E Ponichtera; Mara G Shainheit; Laura I Rutitzky; Miguel J Stadecker
Journal:  Semin Immunopathol       Date:  2012-10-25       Impact factor: 9.623

10.  Coxsackievirus B3-induced myocarditis: differences in the immune response of C57BL/6 and Balb/c mice.

Authors:  Carola Leipner; Katja Grün; Ilka Schneider; Brigitte Glück; Holger H Sigusch; Axel Stelzner
Journal:  Med Microbiol Immunol       Date:  2003-10-31       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.